Drug intelligence / Profile preview

PT-112 + gemcitabine

Development stage: Unknown
Lead developer: Promontory Therapeutics
Modality: Small Molecules
Administration: Intravenous

Overview

PT-112 + gemcitabine is an investigational combination therapy comprising PT-112, a novel pyrophosphate-platinum conjugate, and gemcitabine, a nucleoside metabolic inhibitor. PT-112 is a small molecule chemotherapeutic agent designed to induce immunogenic cell death (ICD) and possesses osteotropic (bone-targeting) properties due to its pyrophosphate moieties. Gemcitabine acts by inhibiting DNA synthesis and ribonucleotide reductase. The combination is primarily being evaluated for the treatment of advanced solid tumors, with a specific focus on biliary tract cancer. It is currently in Phase I/II clinical development, particularly in trials conducted in China (e.g., NCT05357196).

Other names: PT-112 + gemcitabine

Targets

DNARNR (Ribonucleotide reductase)

Beyond the preview

Go deeper on PT-112 + gemcitabine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PT-112 + gemcitabine.

Explore the full profile